GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)
What GlaxoSmithKline files
- Others98
- Investor Meet25
- Updates20
- Important16
- Board Meeting12
- Dividend/Bonus9
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding 'Letter for weblink for Annual Report '.
GlaxoSmithKline Pharmaceuticals Limited has announced a board meeting on the financial results for the quarter and half-year. At the 100th Annual General Meeting, key resolutions were approved, including adoption of audited financial statements, declaration of a final dividend of Rs 42 per share, re-appointment of Mr. Juby Chandy as Director,...
GlaxoSmithKline Pharmaceuticals Limited has announced a board meeting to discuss the financial results for the quarter and half-year. The company is engaging with institutional investors through scheduled analyst meetings to share publicly available information. No new operational changes, business developments, or financial impacts were disclosed.
GlaxoSmithKline Pharmaceuticals has announced a board meeting to discuss the financial results for the quarter and half-year. The company is urging shareholders to update their PAN, KYC, and nomination details to ensure smooth dividend payments. A support cell and toll-free number have been launched to assist senior citizen shareholders.
GlaxoSmithKline Pharmaceuticals strengthened its ESG profile with a 3.3% cut in water use and Zero Liquid Discharge at the Nashik plant. The respiratory portfolio expanded with Trelegy and Nucala auto-injectors, alongside a successful multi-specialty launch of the Shingrix vaccine. Mental wellbeing programs and employee safety training were prioritized. CSR efforts...